These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16583669)

  • 41. Reassessing cancer mortality in Rhode Island, an old urban state.
    Fulton JP
    R I Med; 1995 Nov; 78(11):314-6. PubMed ID: 8547720
    [No Abstract]   [Full Text] [Related]  

  • 42. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS; Soloway CT; Williams S; Ayyathurai R; Kava B; Manoharan M
    BJU Int; 2008 Jan; 101(2):165-9. PubMed ID: 17850361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
    Akaza H
    BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.
    Descazeaud A; Peyromaure M; Salin A; Amsellem-Ouazana D; Flam T; Viellefond A; Debré B; Zerbib M
    Eur Urol; 2008 Feb; 53(2):355-61. PubMed ID: 17611015
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proposed update on substaging metastatic prostate cancer.
    Crawford ED; Connor T
    Urology; 2009 Jul; 74(1):237. PubMed ID: 19567307
    [No Abstract]   [Full Text] [Related]  

  • 47. Height, urban-born and prostate cancer risk in Japanese men.
    Minami Y; Tochigi T; Kawamura S; Tateno H; Hoshi S; Nishino Y; Kuwahara M
    Jpn J Clin Oncol; 2008 Mar; 38(3):205-13. PubMed ID: 18272473
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
    Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
    J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer.
    Zelefsky MJ; Yamada Y; Kollmeier MA; Shippy AM; Nedelka MA
    Eur Urol; 2008 Jun; 53(6):1172-9. PubMed ID: 18222596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How statins may increase prostate cancer.
    Goldstein MR; Mascitelli L; Pezzetta F
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):459. PubMed ID: 18268131
    [No Abstract]   [Full Text] [Related]  

  • 51. Editorial comment on: prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy.
    Rabbani F
    Eur Urol; 2007 Sep; 52(3):723-4. PubMed ID: 17337115
    [No Abstract]   [Full Text] [Related]  

  • 52. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer.
    Gallina A; Chun FK; Suardi N; Eastham JA; Perrotte P; Graefen M; Hutterer G; Huland H; Klein EA; Reuther A; Montorsi F; Briganti A; Shariat SF; Roehrborn CG; de la Taille A; Salomon L; Karakiewicz PI
    BJU Int; 2008 Jun; 101(12):1513-8. PubMed ID: 18422773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The search for better prognostic factors for men treated for localized prostate cancer continues.
    Karakiewicz PI; Suardi N; Shariat SF
    Eur Urol; 2008 Apr; 53(4):689-90. PubMed ID: 18093722
    [No Abstract]   [Full Text] [Related]  

  • 54. MR imaging and MR spectroscopy in prostate cancer management.
    Katz S; Rosen M
    Radiol Clin North Am; 2006 Sep; 44(5):723-34, viii. PubMed ID: 17030223
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer in Rhode Island: common questions, simple answers.
    Fulton JP
    Med Health R I; 2001 Aug; 84(8):277-8. PubMed ID: 11517716
    [No Abstract]   [Full Text] [Related]  

  • 56. Treatment of prostate cancer in unfit senior adult patients.
    Falci C; Morello E; Droz JP
    Cancer Treat Rev; 2009 Oct; 35(6):522-7. PubMed ID: 19487081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reductions in premature mortality, Rhode Island, 1989-1998.
    Buechner JS
    Med Health R I; 2001 Nov; 84(11):374-5. PubMed ID: 12355667
    [No Abstract]   [Full Text] [Related]  

  • 58. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer.
    Lerner SP; Shen S
    Urol Oncol; 2008; 26(5):481-5. PubMed ID: 18774459
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Management of early prostate cancer.
    Stewart A
    Eur J Cancer Care (Engl); 2007 Nov; 16(6):461. PubMed ID: 17944759
    [No Abstract]   [Full Text] [Related]  

  • 60. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.